Has Joseph Muhlestein, MD received payments from drug or device companies?

Yes. Drug and device makers reported $65,147 in general payments to Joseph Muhlestein, MD across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Muhlestein, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Muhlestein, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Muhlestein, MD

Cardiovascular Disease · Murray, UTNPI 1689683435

Payments from drug & device makers

What this record shows

This record is dominated by grants: $54,936 of the $65,147 with a category attached, or 84.3%. Medtronic accounts for 79.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $28,030 and has fallen 95.3% since, to $1,307 in 2025. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,147in general payments, 2019–2025

Across 41 payments — averaging $1588.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$52K
Abbott$5K
Novartis$3K
Boston Scientific$3K
Cook Medical LLC$1K
Merck$236
plus $85 from 1 others

$251,547in research payments, 2019–2025

Across 9 payments — averaging $27,950 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$174K
Vifor Pharma, Inc.$75K
Amgen$3K

What the payments were for

Consulting fees$6001%
Speaking & faculty fees$3,3755%
Grants$54,93684%
Travel & lodging$4,0836%
Food & beverage$2,1093%
Education$440%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	6	$52,011
Abbott	18	$5,217
Novartis	2	$3,404
Boston Scientific	9	$2,952
Cook Medical LLC	1	$1,241
Merck	4	$236
Regeneron Healthcare Solutions, Inc.	1	$85

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,147 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah →

Medicare billing

Part B allowed, 2024

$38,616

Medicare patients

215

Services billed

405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	20	$26,333
FarxigaDapagliflozin Propanediol	26	$24,995
JardianceEmpagliflozin	18	$23,979
MounjaroTirzepatide	11	$11,708
Flecainide Acetate	12	$524
Rosuvastatin Calcium	32	$438
Spironolactone	20	$362
Losartan Potassium	24	$336
Amlodipine Besylate	23	$324
ClopidogrelClopidogrel Bisulfate	17	$235
Amiodarone Hcl	12	$177
Metoprolol Succinate	12	$177
Levothyroxine Sodium	16	$152
Metformin Hcl	21	$148
Atorvastatin Calcium	16	$88

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Murray

Brian WhisenantMurray$416K
Divya Ratan VermaMurray$47K
Kirk KnowltonMurray$18K
Stephen MillerMurray$11K
Travis MossMurray$6K
Jonathan HarrisonMurray$5K
Alpana SenapatiMurray$4K
Kia AfsharMurray$4K
Gary SymkoviakMurray$3K
Rasheel ChowdharyMurray$2K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →